IMV, through its subsidiary, ImmunoVaccine Technologies Inc., is a clinical stage biopharmaceutical company that develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancers. Co. also capitalizes on licensing opportunities of its platform for other applications including infectious diseases. Co.'s proprietary DepoVax adjuvanting/delivery platform is believed to produce an immune response that has a specific and sustained immune effect, and enables Co. to pursue vaccine candidates in cancer, infectious diseases and potentially other vaccine applications. The IMV stock yearly return is shown above.
The yearly return on the IMV stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMV annual return calculation with any dividends reinvested as applicable (on ex-dates).
|